Clinical and functional outcome measures in LAMA2-related muscular dystrophy and SELENON-related myopathy; a 1.5-year natural history study
Journal of Neuromuscular Diseases · 01.08.2026
DOI: 10.1177/22143602261465467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 01.08.2026. Verfasst von Elisabeth C M de Laat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Radboudumc Research Institute for Medical Innovation, Donders Institute for Brain, Cognition and Behaviour, Radboud Universi…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
LAMA2-related muscular dystrophy (LAMA2-MD) and SELENON-related myopathy (SELENON-RM) are rare congenital muscle diseases characterized by slowly progressive proximal muscle weakness, spinal rigidity and respiratory insufficiency. The LAST STRONG study is a natural history study to identify suitable outcome measures and reach trial readiness for LAMA2-MD and SELENON-RM.
Methods
Patients had four visits over 1.5-years. Assessments included neurological examination, hand-held dynamometry (HHD), functional assessments (Motor Function Measurements(MFM)-20/32, graded and timed function tests), accelerometry, and questionnaires on quality of life, activities and participation, pain, and fatigue.
Results
A total of 27 LAMA2-MD (21 years, range 3-50; 9 males) and 11 SELENON-RM (20 years, range 3-42; 8 males) patients were included. In LAMA2-MD, mean HHD scores for neck extensors, biceps brachii, quadriceps, foot plantar flexors and handgrip strength increased (all p < 0.02). In SELENON-RM, biceps brachii and foot plantar flexors increased (p < 0.01). In LAMA2-MD, functional assessments did not change significantly. In SELENON-RM, MFM-20/32 total score and domain 1 decreased (p < 0.05), 6-Minute Walk Test (6MWT) decreased (p < 0.01) and 10-Meter Walk Test (10MWT) increased (p < 0.01). Accelerometry showed a significant change in moderate activity in LAMA2-MD (p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Radboudumc Research Institute for Medical Innovation, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Rehabilitation, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Paediatric Neurology, Donders Institute for Brain, Cognition and Behaviour, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Rehabilitation, Donders Institute for Brain, Cognition and Behaviour, Amalia Children's Hospital, Radboud University Medical Center, Nijmegen, The Netherlands.
ORCID-Profile: Elisabeth C M de Laat, Jan T Groothuis, Karlijn Bouman, Corrie E Erasmus, Nicol C Voermans
Zitieren
APA
de Laat, E. C. M., Groothuis, J. T., Bouman, K., Houwen-van Opstal, S. L. S., Erasmus, C. E., & Voermans, N. C. (2026). Clinical and functional outcome measures in LAMA2-related muscular dystrophy and SELENON-related myopathy; a 1.5-year natural history study. Journal of Neuromuscular Diseases. https://doi.org/10.1177/22143602261465467
Vancouver
de Laat ECM, Groothuis JT, Bouman K, Houwen-van Opstal SLS, Erasmus CE, Voermans NC. Clinical and functional outcome measures in LAMA2-related muscular dystrophy and SELENON-related myopathy; a 1.5-year natural history study. Journal of Neuromuscular Diseases. 2026. doi:10.1177/22143602261465467
BibTeX
@article{deLaat2026,
author = {de Laat, Elisabeth C M and Groothuis, Jan T and Bouman, Karlijn and Houwen-van Opstal, Saskia L S and Erasmus, Corrie E and Voermans, Nicol C},
title = {Clinical and functional outcome measures in LAMA2-related muscular dystrophy and SELENON-related myopathy; a 1.5-year natural history study},
journal = {Journal of Neuromuscular Diseases},
year = {2026},
doi = {10.1177/22143602261465467}
}
EUVIMED